SYRE Spyre Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1636282 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-77.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-35.0%
ROA-32.9%
ROIC (approx.)-29.1%
Asset turnover—
Leverage & solvency
Liabilities / assets4.4%
Debt / equity0.00x
Current ratio27.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $0 |
| R&D expense | $89.17M | $65.50M | $60.41M | $44.64M | $45.25M | $40.15M | $41.62M | $50.48M |
| SG&A expense | $16.55M | $16.14M | $15.23M | $12.53M | $11.64M | $11.79M | $11.94M | $10.77M |
| Operating income | -$105.72M | -$41.64M | -$45.64M | -$57.17M | -$56.89M | -$41.94M | -$53.57M | -$61.25M |
| Pretax income | -$96.12M | -$36.20M | -$69.00M | -$62.53M | -$11.18M | -$36.72M | -$44.79M | -$56.30M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | -$15,000 | $1,000 |
| Net income | -$96.12M | -$36.20M | -$69.00M | -$62.53M | -$11.18M | -$36.72M | -$44.77M | -$56.30M |
| EBITDA | — | — | — | — | — | — | — | -$61.25M |
| EPS (diluted) | — | — | -0.74 | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $82.73M | $162.01M | $97.19M | $85.72M | $64.90M | $81.66M | $48.49M | $89.42M |
| Short-term investments | $989.18M | $983.34M | $644.28M | $670.81M | $421.30M | $444.92M | $516.33M | $513.66M |
| Current assets | $1.10B | $1.17B | $763.95M | $777.78M | $504.60M | $538.83M | $569.77M | $608.47M |
| Total assets | $1.10B | $1.17B | $763.95M | $777.78M | $504.60M | $538.83M | $569.78M | $608.48M |
| Current liabilities | $40.14M | $63.30M | $85.16M | $58.69M | $46.27M | $83.06M | $70.68M | $54.06M |
| Total liabilities | $48.19M | $71.86M | $93.14M | $62.55M | $49.50M | $83.06M | $87.17M | $90.68M |
| Shareholders' equity | $1.05B | $1.10B | $670.81M | $715.24M | $455.10M | $455.77M | $482.61M | $517.80M |
| Shares outstanding | 89.95M | 88.06M | 78.84M | 78.19M | 60.47M | 60.37M | 60.28M | 60.26M |
| Cash flow statement | ||||||||
| Operating cash flow | -$77.50M | -$69.88M | -$57.37M | -$44.58M | -$37.12M | -$46.56M | -$40.99M | -$37.20M |
| Investing cash flow | -$3.80M | -$297.90M | $56.58M | -$247.41M | $25.00M | $79.00M | -$61,000 | -$170.54M |
| Financing cash flow | $2.02M | $432.60M | $12.26M | $312.81M | -$4.64M | $731,000 | $125,000 | $225.60M |
| Depreciation & amortization | — | — | — | — | — | — | — | $0 |
| Stock-based compensation | $14.17M | $13.51M | $12.81M | $9.81M | $9.57M | $9.38M | $8.86M | $9.22M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.